FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Arcturus Therapeutics Shares Fall After Analyst Downgrade Stock”
Arcturus Therapeutics
(NASDAQ: ARCT) plunged over 41% after analysts downgraded the company on disappointing results from a Phase 1/2 trial of its COVID-19 vaccine candidate.
Even though the company had been granted approval from the Singapore Health Sciences Authority to move ahead with a Phase 2 study, analysts were worried that the candidate would not be able to achieve competitive levels of vaccine efficacy with single-shot dosing.
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes s